Aspen absorbs mRNA hit, eyes sharper second-half recovery

Aspen Pharmacare has delivered what it describes as a transitional set of interim results for the six months ended 31 December 2025 as the group absorbs the impact of a concluded mRNA contract and major restructuring costs.

Despite a 4% decline in reported revenue to R21.1 billion, the pharmaceutical giant remains optimistic, forecasting a significantly stronger second half as its manufacturing “reshaping” begins to pay dividends.

Read: Aspen flags interim earnings slide but sticks to growth outlook

mRNA void and restructuring costs

The group’s bottom line was hit by a “high base” in the prior year, which included a R1.5 billion contribution from a subsequently cancelled mRNA manufacturing contract.

Normalised group earnings before interest, tax, depreciation and amortisation(Ebitda) fell 13% to R5.1 billion, an outcome the company noted was consistent with previous market guidance.

Profitability was further suppressed by R695 million in once-off restructuring costs tied to the sterile finished dose form (FDF) manufacturing facilities in South Africa and France. Consequently, headline earnings per share (Heps) dropped 35% to 417.4 cents, while basic earnings per share (EPS) declined 38% to 331.1 cents.

Commercial pharmaceuticals: A strong engine

While manufacturing faced headwinds, Aspen’s material business segment, commercial pharmaceuticals, demonstrated resilient momentum. The segment delivered 4% revenue growth (reaching R16.6 billion) and an 11% surge in normalised Ebitda at constant exchange rates (CER).

Performance was bolstered by strong organic demand for Mounjaro in South Africa and an improved profit contribution from a reshaped business in China.

Read: Aspen Pharmacare hopes weight loss product will fatten profits

However, these operational gains were somewhat diluted by the relative strength of the South African rand against most of Aspen’s major trading currencies during the period.

Apac divestment

A major strategic pivot for the group is the pending Au$2.37 billion divestment of its Asia Pacific (Apac) business. Announced in late 2025, the deal is expected to complete by the end of May 2026, subject to shareholder approval.

Read: Aspen jumps over 24% on R26.5bn Asian asset sale

The proceeds from this sale are slated to effectively eliminate most of the group’s net debt, which currently stands at R28.6 billion. Management believes this will create vital balance sheet flexibility to support future capital allocation and drive long-term shareholder value.

Outlook: Targeting a double-digit recovery

Looking ahead, Group CEO Stephen Saad and the board anticipate that normalised CER Ebitda for the full year will at least double the first-half figure of R3.8 billion.

This forecast is supported by anticipated double-digit growth in normalised headline earnings for FY2026.

In Manufacturing, the group expects commercial production of insulin in its South African sterile facility to receive final regulatory approval in the first quarter of calendar year 2026. By FY2027, the currently loss-making sterile FDF facilities in France and South Africa are targeted to reach a positive normalised Ebitda and cash flow position.